Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ROIV |
---|---|---|
09:32 ET | 90357 | 11.63 |
09:34 ET | 25045 | 11.63 |
09:36 ET | 14629 | 11.57 |
09:38 ET | 13970 | 11.61 |
09:39 ET | 31554 | 11.535 |
09:41 ET | 63325 | 11.535 |
09:43 ET | 53760 | 11.515 |
09:45 ET | 33028 | 11.5 |
09:48 ET | 21607 | 11.52 |
09:50 ET | 30379 | 11.475 |
09:52 ET | 39076 | 11.435 |
09:54 ET | 37345 | 11.44 |
09:56 ET | 14650 | 11.47 |
09:57 ET | 44633 | 11.445 |
09:59 ET | 30984 | 11.455 |
10:01 ET | 54793 | 11.51 |
10:03 ET | 148646 | 11.505 |
10:06 ET | 91961 | 11.51 |
10:08 ET | 28436 | 11.49 |
10:10 ET | 12894 | 11.495 |
10:12 ET | 15591 | 11.505 |
10:14 ET | 16797 | 11.48 |
10:15 ET | 7988 | 11.48 |
10:17 ET | 8276 | 11.5 |
10:19 ET | 10354 | 11.485 |
10:21 ET | 9260 | 11.495 |
10:24 ET | 14573 | 11.52 |
10:26 ET | 77239 | 11.5 |
10:28 ET | 27055 | 11.51 |
10:30 ET | 10704 | 11.505 |
10:32 ET | 25760 | 11.51 |
10:33 ET | 9046 | 11.495 |
10:35 ET | 9902 | 11.505 |
10:37 ET | 11390 | 11.505 |
10:39 ET | 4923 | 11.515 |
10:42 ET | 5414 | 11.515 |
10:44 ET | 9479 | 11.52 |
10:46 ET | 4294 | 11.54 |
10:48 ET | 7291 | 11.535 |
10:50 ET | 24888 | 11.5354 |
10:51 ET | 10128 | 11.53 |
10:53 ET | 98236 | 11.53 |
10:55 ET | 4500 | 11.54 |
10:57 ET | 8067 | 11.525 |
11:00 ET | 91526 | 11.535 |
11:02 ET | 8016 | 11.535 |
11:04 ET | 11518 | 11.545 |
11:06 ET | 11908 | 11.545 |
11:08 ET | 4359 | 11.555 |
11:09 ET | 9770 | 11.545 |
11:11 ET | 8375 | 11.545 |
11:13 ET | 2678 | 11.555 |
11:15 ET | 26974 | 11.54 |
11:18 ET | 2768 | 11.545 |
11:20 ET | 15596 | 11.545 |
11:22 ET | 6825 | 11.5236 |
11:24 ET | 21069 | 11.52 |
11:26 ET | 20711 | 11.525 |
11:27 ET | 9006 | 11.51 |
11:29 ET | 951 | 11.515 |
11:31 ET | 49511 | 11.5 |
11:33 ET | 85637 | 11.5 |
11:36 ET | 41311 | 11.515 |
11:38 ET | 15783 | 11.5 |
11:40 ET | 19185 | 11.5 |
11:42 ET | 15829 | 11.495 |
11:44 ET | 6963 | 11.515 |
11:45 ET | 3792 | 11.525 |
11:47 ET | 21394 | 11.54 |
11:49 ET | 11908 | 11.535 |
11:51 ET | 14746 | 11.535 |
11:54 ET | 32273 | 11.54 |
11:56 ET | 7680 | 11.53 |
11:58 ET | 1690 | 11.54 |
12:00 ET | 3536 | 11.545 |
12:02 ET | 17964 | 11.54 |
12:03 ET | 3791 | 11.555 |
12:05 ET | 20290 | 11.55 |
12:07 ET | 6849 | 11.545 |
12:09 ET | 2839 | 11.545 |
12:12 ET | 7502 | 11.535 |
12:14 ET | 8443 | 11.5203 |
12:16 ET | 41810 | 11.5212 |
12:18 ET | 21217 | 11.52 |
12:20 ET | 611 | 11.52 |
12:21 ET | 29165 | 11.515 |
12:23 ET | 7288 | 11.515 |
12:25 ET | 1588 | 11.515 |
12:27 ET | 1200 | 11.51 |
12:30 ET | 2932 | 11.515 |
12:32 ET | 8664 | 11.505 |
12:34 ET | 5545 | 11.5 |
12:36 ET | 16770 | 11.5 |
12:38 ET | 5332 | 11.51 |
12:39 ET | 28810 | 11.515 |
12:41 ET | 7400 | 11.515 |
12:43 ET | 7222 | 11.505 |
12:45 ET | 792 | 11.51 |
12:48 ET | 400 | 11.505 |
12:50 ET | 26831 | 11.5 |
12:52 ET | 6911 | 11.505 |
12:54 ET | 5280 | 11.5 |
12:56 ET | 4354 | 11.51 |
12:57 ET | 1516 | 11.505 |
12:59 ET | 1810 | 11.505 |
01:01 ET | 4720 | 11.505 |
01:03 ET | 20255 | 11.505 |
01:06 ET | 8704 | 11.51 |
01:08 ET | 1000 | 11.505 |
01:10 ET | 12614 | 11.505 |
01:12 ET | 5751 | 11.51 |
01:14 ET | 5266 | 11.51 |
01:15 ET | 1778 | 11.52 |
01:17 ET | 11261 | 11.515 |
01:19 ET | 6674 | 11.52 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Roivant Sciences Ltd | 8.6B | 2.1x | --- |
Corcept Therapeutics Inc | 4.5B | 38.1x | +9.80% |
Ligand Pharmaceuticals Inc | 1.8B | 44.1x | -12.71% |
Harrow Inc | 1.6B | -46.8x | --- |
Ocular Therapeutix Inc | 1.4B | -8.0x | --- |
Immunocore Holdings PLC | 1.5B | -28.8x | --- |
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 for the treatment of dermatomyositis and non-infectious uveitis, in addition to other clinical-stage molecules. It advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its pipeline program also includes Mosliciguat.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $8.6B |
---|---|
Revenue (TTM) | $158.3M |
Shares Outstanding | 739.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.25 |
EPS | $5.57 |
Book Value | $7.40 |
P/E Ratio | 2.1x |
Price/Sales (TTM) | 54.0 |
Price/Cash Flow (TTM) | 1.8x |
Operating Margin | 2,799.07% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.